GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Shiller PE Ratio

Galectin Therapeutics (FRA:PHPN) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Galectin Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Galectin Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Shiller PE Ratio Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galectin Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Galectin Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Shiller PE Ratio falls into.



Galectin Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Galectin Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Galectin Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.147/129.4194*129.4194
=-0.147

Current CPI (Dec. 2023) = 129.4194.

Galectin Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.195 99.695 -0.253
201406 -0.125 100.560 -0.161
201409 -0.132 100.428 -0.170
201412 -0.146 99.070 -0.191
201503 -0.203 99.621 -0.264
201506 -0.187 100.684 -0.240
201509 -0.232 100.392 -0.299
201512 -0.174 99.792 -0.226
201603 -0.216 100.470 -0.278
201606 -0.178 101.688 -0.227
201609 -0.143 101.861 -0.182
201612 -0.152 101.863 -0.193
201703 -0.140 102.862 -0.176
201706 -0.125 103.349 -0.157
201709 -0.109 104.136 -0.135
201712 -0.059 104.011 -0.073
201803 -0.097 105.290 -0.119
201806 -0.094 106.317 -0.114
201809 -0.060 106.507 -0.073
201812 -0.070 105.998 -0.085
201903 -0.177 107.251 -0.214
201906 -0.053 108.070 -0.063
201909 -0.045 108.329 -0.054
201912 -0.108 108.420 -0.129
202003 -0.054 108.902 -0.064
202006 -0.098 108.767 -0.117
202009 -0.085 109.815 -0.100
202012 -0.107 109.897 -0.126
202103 -0.092 111.754 -0.107
202106 -0.125 114.631 -0.141
202109 -0.119 115.734 -0.133
202112 -0.106 117.630 -0.117
202203 -0.154 121.301 -0.164
202206 -0.151 125.017 -0.156
202209 -0.141 125.227 -0.146
202212 -0.170 125.222 -0.176
202303 -0.177 127.348 -0.180
202306 -0.138 128.729 -0.139
202309 -0.225 129.860 -0.224
202312 -0.147 129.419 -0.147

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galectin Therapeutics  (FRA:PHPN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Galectin Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (FRA:PHPN) Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines